Navigation Links
DuPont Pledges $250,000 to Nature Conservancy for Water Quality Initiative
Date:10/10/2007

grant from DuPont will match funds pledged by The Kresge Foundation to the Campaign for Conservation: Saving the Last Great Places in Iowa. It is contingent on the Conservancy reaching its $9.5 million campaign goal by Feb. 1, 2008.

"Agriculture is making tremendous strides in protecting the environment," said Dean Oestreich, DuPont vice president and general manager and president of Pioneer Hi-Bred. "Today farmers are using conservation tillage, buffer strips, terraces and other means to hold the soil and nutrients in place. But we know there is more agriculture can do. This pledge looks at ways we can continue to improve nutrient management and water quality in a sustainable manner without impacting farmer productivity and profitability."

In addition to financial support, DuPont and its Pioneer business will be actively involved in the project by providing agriculture expertise and engaging farmers to work in the project.

The Boone River watershed encompasses about 581,110 acres in six central counties in Iowa, which flows into the Des Moines River then into the Mississippi River. Funding from DuPont will begin implementation of a three-phase monitoring plan within the Boone River watershed to help develop the measurable ecological restoration goals at the watershed scale.

The Mackinaw River drains the fourth largest watershed of the Illinois River system with almost 740,000 acres. This watershed contains some of the most productive agricultural land in the United States. Nearly 80 percent of the watershed currently is in highly productive agriculture of corn and soybeans.

As a part of its 2015 Sustainability Goals, DuPont has committed to reducing water consumption by at least 30 percent over the next 10 years at its global sites where the renewable freshwater supply is either scarce or stressed as determined by the United Nations analysis of river basins globally. For all other sites, DuPont will hold water consumption flat on an ab
'/>"/>

SOURCE DuPont
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. George Bush pledges 200 million dollars for AIDS relief
2. Buddhadeb pledges to donate his body
3. Teenagers Often Deny Taken ‘Virginity Pledges
4. Gates Foundation Pledges $3 Million to Fight Malaria in Africa
5. Robert Wood Johnson Foundation Pledges $500M To Fund Anti-Obesity Programs
6. Germany Pledges 5.4 Billion Dollars for AIDS Fund
7. Blindness may be genetic by nature
8. Children who snore may be hyperactive by nature
9. Predicting Breast Cancer Recurrence By Understanding Gene Signature
10. Reaction To ADHD Medication May Be Genetic By Nature
11. Risk Of Stroke May Be Genetic By Nature
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)... SEATTLE, Dec. 5 Cell T...q and MTA: CTIC) today announced that that its Boa...Auction" tender offer to,purchase a portion or al...) as,follows: , , -- 4% Convertible Senior...ible Senior Notes due 2011, -- 6.75% Convertib...
(Date:12/4/2008)... , Patients with idiopathic pulmonary fibrosis (I... coronary eventsincluding heart attacksthan people...that analyzed the risk of cardiovascular disease i...00 matched controls. , "If you look at them over...ncreased risk of acute coronary syndrome, which is...
(Date:12/4/2008)... , Early detection of lung disease in cystic fibr...nfants, may be the key to controlling the progress...ew research shows that contrary to previous scient...ts can begin as early as infancy even though lung ...We might be able to stop some of the lung function...
(Date:12/4/2008)... NEW DELHI, India, Dec. 5 /PRNewswire-USNewswire/... Organization today launched a global partnership ...afer, accurate and affordable alternatives. , ...he South Asian Conference on Alternatives to Mercu...rganizations and the Indian NGO Toxics Link. , ...
Breaking Medicine News(10 mins):Health News:Cell Therapeutics, Inc. to Offer to Repurchase up to $124 Million of Its Notes 2Health News:Cell Therapeutics, Inc. to Offer to Repurchase up to $124 Million of Its Notes 3Health News:Double threat: Deadly lung disease also linked to heart attacks 2Health News:Intervention in infants with cystic fibrosis key to slowing progression 2Health News:Intervention in infants with cystic fibrosis key to slowing progression 3Health News:Health Care Without Harm, WHO Announce Partnership for Global Reduction of Mercury-Based Medical Devices 2
...ave been able to generate human skin tissues, whic...ncer//. The researchers for the study feel that th...enic potential of genes in development of skin can...f skin cancer that results from the cells called m...
...rom University of Liverpool had proposed that pati...efit from medication.// They say that it is advisa...ileptic patients. Researchers of the study feel th...gnificantly benefit the patients in having a bette...
...eating HIV/AIDS patients with highly active antire...f the cardiac risks involved, says researchers fro...can dramatically improve the quality of a HIV/AIDS...specially helpful for patients with advanced HIV-1...
...suffering from head and neck cancer who are underg...edication to fight oropharyngeal candidiasis. Orop... mouth caused by the yeast Candida. This condition... of the disease are the formation of white plaques...
Other Medicine News:
(Date:12/4/2008)... PARK, Calif., Dec. 4 Long-term da...expected decrease in Mitral Vale Area (MVA),after...tral regurgitation (MR),is not associated with cl...,with two years of follow-up, none of the patien...surgery for mitral stenosis. At 12 months no,impo...
(Date:12/3/2008)...igna front-line data demonstrating potential in ne...e of leukemia to be featured in two oral sessions ...benefits for chronically transfused patients by si...y organs , , - New long-term data from majo...rt on optimal post-surgery treatment strategy, Fem...
(Date:12/3/2008)...GEVILLE, Pa., Dec. 3 Wye...WYE ), announced today that it has submitted a,ma...opean Medicines Agency,(EMEA) for approval to mar...njugate vaccine (PCV13) for infants and young chil...vention of pneumococcal disease (PD) caused by the...
(Date:12/2/2008)...GO, Dec. 3 Researchers ...the circuitry in the area of the brain,responsibl...nts suffering from,stress-related psychiatric dis...day at the annual meeting of the Radiological Soci...ts with major depression and other stress-related ...
Breaking Medicine Technology:Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 2Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 3Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 2More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 3More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 5More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 6More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 7More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 8More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 9More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 10More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 11More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 12More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 13More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 14More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 15More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 16More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 17More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 18More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 19More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 20More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 21More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 22Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 2Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 3Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 4Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 5Stress-Related Disorders Affect Brain's Processing of Memory 2Stress-Related Disorders Affect Brain's Processing of Memory 3Gerson Lehrman Group Announces Partnership With BIO to Provide Scientific Expertise for the BIO CEO 26 Investor Conference 2725 1Gerson Lehrman Group Announces Partnership With BIO to Provide Scientific Expertise for the BIO CEO 26 Investor Conference 2725 2Gerson Lehrman Group Announces Partnership With BIO to Provide Scientific Expertise for the BIO CEO 26 Investor Conference 2725 3Rochester Medical Announces First Quarter 2008 Earnings Conference Call February 4 2008 10053 1Rochester Medical Announces First Quarter 2008 Earnings Conference Call February 4 2008 10053 2Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 2724 1Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 2724 2Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 2724 3Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 2724 4Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 1Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 2Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 3Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 4Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 5Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 6
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
Medicine Products: